REG - Solvonis Therapeutic - SVN-114 selected for PTSD discovery programme

Solvonis TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ9244Va&default-theme=true

RNS Number : 9244V  Solvonis Therapeutics PLC  10 March 2026

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

10 March 2026

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

SVN-114 selected as the lead candidate for PTSD discovery programme
Novel compound from patent-pending SVN-SDN-14 series targeting a major global
mental health disorder

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, announces the selection of SVN-114 as the lead
candidate from the Company's proprietary SVN-SDN-14 discovery programme
targeting Post-Traumatic Stress Disorder ("PTSD"), a condition affecting more
than 20 million people worldwide for which effective pharmacological treatment
options remain limited.

 

The selection follows compelling pharmacology results from preclinical studies
conducted by Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT), in which
SVN-114 demonstrated balanced modulation of serotonin ("SERT"), dopamine
("DAT") and noradrenaline ("NET"), key brain chemicals involved in mood,
emotion and social behaviour.

 

Following review of the pharmacology data, the Company's Scientific Advisory
Committee, led by Professor David Nutt, agreed to designate SVN-114 as the
programme's lead candidate, marking an important milestone for Solvonis'
proprietary CNS discovery platform.

 

Mechanism designed to support therapeutic engagement

The SVN-SDN-14 series is a class of serotonin ("SERT"), dopamine ("DAT") and
noradrenaline ("NET") modulators designed to enhance pro-social behaviour and
improve therapeutic outcomes for people living with PTSD..

 

By modulating neurochemical pathways associated with trust, empathy and social
bonding, compounds in this series, including SVN-114, are intended to help
patients rebuild interpersonal relationships and engage more effectively in
therapy.

 

Novel chemistry supported by international patent applications

SVN-114 originates from a proprietary chemical series discovered through
Solvonis' internal research programme. Composition-of-matter patent
applications have been filed internationally covering both the compound class
and its pharmaceutical applications.

 

The Company believes the intellectual property associated with this compound
series provides a strong foundation for the development of first-in-class or
best-in-class therapeutics targeting trauma-related psychiatric disorders in
area of significant unmet clinical need and growing market demand.

 

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "The
identification of SVN-114 as the lead candidate from this compound series
represents an important step forward for the programme.

 

"The compound has demonstrated a robust pharmacological profile across
serotonin, dopamine and noradrenaline systems in both in vitro and in vivo
testing. These neurotransmitter systems are central to the neurobiology of
trauma and social behaviour, and targeting them in a controlled way may open a
new therapeutic avenue for the treatment of PTSD.

 

"The broader chemical series also continues to show scientific promise, and we
look forward to further exploring the potential of this compound class."

 

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "The selection
of SVN-114 as the lead candidate from our PTSD discovery programme highlights
the strength of Solvonis' proprietary CNS discovery platform.

 

"Importantly, this compound emerges from a chemical series supported by
international composition-of-matter patent applications, providing a strong
intellectual property foundation and long-term commercial potential.

 

"PTSD represents a major global mental health challenge affecting millions of
people and remains an area of significant unmet medical need. We believe
SVN-114 has the potential to offer a differentiated therapeutic approach in
this area."

 

 

Enquiries:

 

 Solvonis Therapeutics plc                                       Via Walbrook
 Anthony Tennyson, CEO & Executive Director

 Singer Capital Markets (Broker)                                 +44 (0) 20 7496 3000
 Phil Davies

 Walbrook PR (PR/IR advisers)  Tel: +44 (0)20 7933 8780 or solvonistherapeutics@walbrookpr.com
                               (mailto:solvonistherapeutics@walbrookpr.com)
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001
 Lianne Applegarth                                               Mob: +44 (0)7584 391 303
 Rachel Broad                                                    Mob: +44 (0)7747 515 393

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

 

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

 

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

 

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKLFBQXLXBBD



            Copyright 2019 Regulatory News Service, all rights reserved